Literature DB >> 1597861

Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.

A Liu1, K E Carlson, J A Katzenellenbogen.   

Abstract

We have prepared nine androgens substituted with fluorine at C-16 or C-20 to evaluate their potential, as positron emission tomographic (PET) imaging agents for prostatic cancer when labeled with the positron emitting radionuclide fluorine-18 (t1/2 = 110 min). These compounds represent members from the following classes of androgens: testosterone (T), 5 alpha-dihydrotestosterone (DHT), 7 alpha-methyl-19-nortestosterone (MNT), mibolerone (Mib), and metribolone (R1881). All of these compounds were prepared by functionalization of suitable androgen precursors, and the synthetic routes were developed to allow the introduction of fluorine by a fluoride ion displacement reaction late in the synthesis, as is required for the preparation of these compounds in fluorine-18 labeled form. We have also prepared four androgens in which the C-3 carbonyl or 17 beta-hydroxyl groups are replaced by fluorine. Most of the fluorine-substituted androgens show high affinity for the androgen receptor (AR), although fluorine substitution lowers their affinity by a small factor. None of the androgens where fluorine replaces oxygen functions at C-3 or C-17 have substantial affinity for AR. Derivatives of the natural androgens (T and DHT) as well as MNT have little affinity for other steroid hormone receptors (progesterone and mineralocorticoid receptors), whereas the Mib and R1881 derivatives have somewhat greater heterologous binding. With sex steroid binding protein, a human serum binding protein, the pattern of binding affinities is nearly the reverse, with derivatives of Mib, R1881 and MNT having low affinity, and DHT and T, high affinity. From these fluorine-substituted compounds, we can select several whose preparation in fluorine-18 labeled form for further tissue distribution studies is merited.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597861     DOI: 10.1021/jm00089a024

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.

Authors:  Mark Lazari; Serge K Lyashchenko; Eva M Burnazi; Jason S Lewis; R Michael van Dam; Jennifer M Murphy
Journal:  Appl Radiat Isot       Date:  2015-05-21       Impact factor: 1.513

2.  Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.

Authors:  Robert D Bruno; Tadas S Vasaitis; Lalji K Gediya; Puranik Purushottamachar; Abhijit M Godbole; Zeynep Ates-Alagoz; Angela M H Brodie; Vincent C O Njar
Journal:  Steroids       Date:  2011-06-24       Impact factor: 2.668

3.  Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies.

Authors:  Zhenghong Peng; David Maxwell; Duoli Sun; Yunming Ying; Paul T Schuber; Basvoju A Bhanu Prasad; Juri Gelovani; Wai-Kwan Alfred Yung; William G Bornmann
Journal:  Tetrahedron       Date:  2014-01-28       Impact factor: 2.457

4.  Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging.

Authors:  Ziqi Zhu; Yoon-Mi Chung; Olga Sergeeva; Vladimir Kepe; Michael Berk; Jianneng Li; Hyun-Kyung Ko; Zhenfei Li; Marianne Petro; Frank P DiFilippo; Zhenghong Lee; Nima Sharifi
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

5.  Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.

Authors:  Dong Zhou; Mai Lin; Norio Yasui; Mohammed H Al-Qahtani; Carmen S Dence; Sally Schwarz; John A Katzenellenbogen
Journal:  J Labelled Comp Radiopharm       Date:  2014-02-17       Impact factor: 1.921

6.  Production of diverse PET probes with limited resources: 24 18F-labeled compounds prepared with a single radiosynthesizer.

Authors:  Jeffrey Collins; Christopher M Waldmann; Christopher Drake; Roger Slavik; Noel S Ha; Maxim Sergeev; Mark Lazari; Bin Shen; Frederick T Chin; Melissa Moore; Saman Sadeghi; Michael E Phelps; Jennifer M Murphy; R Michael van Dam
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-10       Impact factor: 11.205

Review 7.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

8.  Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors.

Authors:  Jillian R Gunther; Alexander A Parent; John A Katzenellenbogen
Journal:  ACS Chem Biol       Date:  2009-06-19       Impact factor: 5.100

Review 9.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

10.  Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Jessica Nearman; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.